Citations

Showing 10 of 108104 citations.

The Challenges of Providing Interventional Radiology Services to Rural and Smaller Community Hospitals
Cook, Philip S. , Cook, Philip S.

Mayo Clinic

American Journal of Roentgenology | July 24, 2018 | Volume: 211 | Issue: 4 | Pages: 744-747

10.2214/ajr.18.20092 | PMID 30040470 Get It

Discrepancies in Self-Reported and Actual Conflicts of Interest for Robotic Pediatric Urological Surgery
Jimbo, Masaya , Granberg, Candace F. , Osumah, Tijani , Bandari, Jathin , Cannon, Glenn M., Gargollo, Patricio C. , Osumah, Tijani S, Routh, Jonathan C.

Mayo Clinic

Journal of Urology | July 24, 2018 | Volume: 201 | Issue: 2 | Pages: 393-399

10.1016/j.juro.2018.07.043 | PMID 30053509 Get It

The Effect Of Antiporcine Willebrand Factor Monoclonal Antibodies On The Bleeding Time
Bowie, Ejw, Fass, David N., Katzmann, J A

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652458 Get It

Murine monoclonal antibodies to porcine Willebrand factor were used to study the role of Willebrand factor in hemostatic plug formation in the in vivo and in vitro skin bleeding times. The in vivo assay requires the intravenous injection of antibody-containing mouse ascitic fluids into normal animals with subsequent ear bleeding time tests performed over a 24-hour period. The in vitro assay was carried out with heparinized normal porcine blood flowing through a 0.5 cm incision in an excised piece of porcine skin. The heat inactivated ascitic fluids, containing the antibodies, were used ;Ln these assays at final dilutions of 2 × 102 through 2 × 105 The 7 antibodies used comprised at least 5 groups with differing reactivities based on assays other than bleeding time tests. The antibody titers in a poreineg Willebrand factor-binding radioimmunoassay ranged from 108 through 1012 . Doses of 10HL of ascitic fluid/kg of body weight (approximately 2 × 103 final dilution) were able to transiently prolong the in vivo bleeding time without alteration of other VIII complex values (VIII:C, ristocetin cofactor activity and Vlll-related antigen). Higher doses resulted in bleeding times similar to von Willebrand pigs (>15 min) immediately following infusion, with a decay of the effect over the next 2 hours. At dilutions of 2 × 104 selected monoclonal antibodies interfered with hemostasis in the in vitro model whereas other antibodies inhibited only at 2 × 102 dilution. With one exception, the potencies of the antibodies appeared to be similar in both assays. The titer of the antibodies in the radioimmunoassay does not appear to correlate with prolongation of the in vitro bleeding time, suggesting specific reactivity with functional sites involved in hemostatic plug formatio.
Improvement Of Shortened Platelet Survival Half-Life From The Early To The Late Phase Of Myocardial Infarction
Chesebro, James H., Byrne, John , Fuster, Valentı́n

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652392 Get It

The incidence of reinfarction, death and systemic thromboembolism is greatest in the first 2 months after acute myocardial infarction and decreases with time after infarction. Reasons for this are unknown, but increased platelet vascular wall interaction may be a contributing factor. Thirteen patients, mean age 53 years, had a platelet survival determination (platelet half-life calculated by least square analysis) within 1 month (mo) after acute, uncomplicated myocardial infarction (10 transmural, 3 subendocardial); a platelet survival study was repeated 3-8 mo (average 4 mo) later. All patients were on oral anticoagulants and during the time of observation none of the patients had any clinical thromboembolic events.Ten of the 13 patients had a shortened (<92 hours) platelet survival half-life of 75 hours (avg) within 1 mo after myocardial infarction which increased significantly (P<.01) to 94 hours (avg) four mo (avg) later. Ten control patients with angiographically proven coronary artery disease, stable angina pectoris, and a shortened platelet survival of 85 hours (avg) had a repeat platelet survival 6 mo later that was not significantly changed (mean variability 5%).The shortened platelet survival that improves with time after myocardial infarction is compatible with the increased incidence of reinfarction, death and thromboembolism early after myocardial infarction. Whether the increased platelet consumption reflects platelet deposition in the coronary vessels or in the left ventricle (as a mural thrombus) is at present under investigation with imaging of III-Indium-labeled platelets.
The Teflon Tubing Bleeding Time In Man
Didisheim, Paul, Claypool, D.A., Stropp, J. Q., Baker, Robert W.

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652349 Get It

The skin bleeding time (BT)(Mielke, Ivy, Duke) is an important part of the diagnostic workup of bleeding disorders. Because of variable vascularity of the skin from one location to another, results may vary widely with the site and type of incision and the thickness of the skin. In some patients bleeding is difficult to stop. The discomfort of the test and the possibility of inducing scarring limit the frequency with which it can be repeated. A standardized BT that could be performed on the patient’s blood in the laboratory could avoid these problems. We have developed such a test, basing it on our previously described method in which a hole is made in a Teflon arteriovenous shunt in rats, and modified from the method of Blakely et al. A cylindrical hole of 75 μ diameter is made in a 50 cm length of 457 μ I.D. Teflon tubing with the aid of a needle, micromanipulator and dissecting microscope. Blood (2 U heparin/ml) from normal human subjects displaces buffer from the tubing at a rate (.6 ml/min) determined by a syringe pump. Pressure is controlled by raising the distal end of the tubing 5 cm above the hole. BT is recorded by an electronic drop rate counter (Payton BTR 400). Under these conditions, BT is 150 ± 47 sec, and bleeding rate from the hole, shear rate and shear stress on the wall of the hole are .11 ± .02 ml/ min, 40,700 ± 8,100 sec-1 and 1,830 ± 360 dynes/cm2 respectively. The BT can be varied from 0 to >15 min by lowering or raising pressure or flow in the system or by varying hole diameter. By phase microscopy the hole is seen to be occluded by a mass of aggregated platelets and occasional PMN. These observations show that hemostasis at small incisions is controlled by rheologic factors and platelets and does not require physical or chemical properties of a blood vessel. This new method may be useful in the diagnosis of bleeding disorders and in studying the effects of rheologic factors and drugs in hemostasis.
Role Of Verapamil (Calcium Blocker) In The Reduction Of Platelet Deposition In Gore-Tex Grafts In Dogs
Dewanjee, Mrinal K., Murphy, K., Vlietstra, Ronald E., Didisheim, Paul, Kaye, Michael P., Fuster, Valentı́n

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652261 Get It

Platelet calcium appears to be essential in platelet activation. Accordingly, Verapamil (a channel calcium blocker) was tested “in vivo” as a possible platelet inhibitor agent. Fifteen dogs underwent bilateral femoral artery grafting with one polytetrafluoroethylene (Gore-Tex) and one autologous vein graft. Peroperatively, five dogs were infused continuously with Verapamil (6 μgs/kg/min) and 9 dogs were left untreated and the arterial prostheses were surgically implanted. Using autologous Indium-111-labeled platelets injected 24 hours prior to surgery as a platelet marker, grafts were removed 1 hour following resumption of blood flow. Radioactivity per unit weight of Gore-Tex, vein and blood were determined with a gamma counter and the relative radioactivity with respect to the internal reference standard of blood is tabulated belowVerapamil-treated dogs showed a significant reduction in the “in vivo” platelet deposition on Gore-Tex and autologous venous grafts. Preliminary data indicates that “in vitro” platelet aggregation with soluble calf skin collagen (515 μg/ml) and ADP (2-100 μm) is not different between control and drug-treated dogs.Calcium channel blockers may be promising “in vivo” platelet inhibitor agents; in addition, they may provide further understanding of the different processes involved in “in vivo” and “in vitro” platelet activation.
The Thrombin Catalyzed Activation Of Human Factor V Probed With A Hybridoma Antibody
Katzmann, J A, Nesheim, Michael E., Mann, K G

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1652213 Get It

The peptides produced during the thrombin (IIa) catalyzed activation of human Factor V (HFV) were investigated using a murine monoclonal antibody. This antibody (HFV-1) binds HFV and activated HFV (HFVa) and releases them at high ionic strength. HFV-1 coupled to sepharose was used to purify the single chain, 330,000 apparent MW procofactor molecule. Gel electrophoresis in SDS indicated that IIa- mediated activation proceeded with the appearance of intermediates with apparent MW of 270K, 205K and 150K and resulted in at least 3 end products with apparent MW of 110K, 93K and 70K. Aliquots of partially and fully activated HFV were chromatographed on the HFV-1 affinity resin. The peptides not associated with HFVa were obtained by washing the column with 20 mM imidazole, 0.154 M NaCl, 5 mM CaCl2, pH 6.5; the peptides noncovalently bound to the epitope-containing peptides were obtained by elution in the above buffer made 5 mM EDTA in place of Ca++ and the epitope-containing peptides were eluted in buffer made 1.2 M in NaCl. The 150K intermediate was released in EDTA and the 205K and 270K peptides were eluted in high salt. Of the end products of activaion, the 110K peptide was not retained by the coliman, the 93K peptide was released in EDTA, and the 70K peptide was released only at high ionic strength. These data indicate that the 270K and 205K intermediates, and the 70K end product share the antigenic site involved in the interaction with the monoclonal antibody. In addition a Ca++- dependent interaction between the epitope-containing domain and the 150K intermediate and 93K end product is suggested. From this data and by analogy with the bovine protein, we suggest that HFVa is a Ca++-dependent multiple subunit protein consisting minimally of two peptides of apparent MW of 93,000 and 70,000.
Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development
Klingner, Kerstin, Bug, Daniel, Zoeller, Caren, Maier, Armin, Dong, Meng , Willecke, Kerstin, Steiner, Eva, Landesfeind, Manuel, Copland, John A. , Siegers, Gabrielle M. , Haferkamp, Axel, Böehm, Katharina , Schneider, Meike , Schüler, Julia B. , Peille, Anne-Lise , Tsaur, Igor

Mayo Clinic

Oncotarget | July 24, 2018 | Volume: 9 | Issue: 57 | Pages: 30946-30961

10.18632/oncotarget.25697 | PMID 30123419 Get It

Comparison of Practice Patterns between Inpatient Cardiology Pharmacists with and without Added Qualifications in Cardiology
Lose, Jennifer M., Dorsch, Michael P. , Lose, Jennifer, DiDomenico, Robert J.

Mayo Clinic

Hospital Pharmacy | July 24, 2018 | Volume: 50 | Issue: 1 | Pages: 051-058

10.1310/hpj5001-51 | PMID 25684801 Get It

Background There is a paucity of data comparing practice patterns between board-certified specialists with added qualifications in cardiology (AQCV) and cardiovascular pharmacists without these credentials. Purpose The purpose is to characterize differences in practice between inpatient pharmacists with and without AQCV. Methods We conducted a multicenter, retrospective, cross-sectional, case-controlled survey. An AQCV pharmacist list was extracted from the Board of Pharmacy Specialties Web site. Hospitals with AQCV pharmacists comprised the case group. Hospitals were excluded if the AQCV pharmacists did not provide direct patient care, practiced in the outpatient setting, or were in a Veterans Affairs hospital. Each case hospital was matched to hospitals without an AQCV pharmacist in a 1:3 ratio (case:control) by region, cardiovascular discharges, and teaching hospital status. Institutions completed a survey characterizing their pharmacy services. Results Fifty-six hospitals completed the survey (21 AQCV, 35 non-AQCV). More AQCV pharmacists participated on rounds (100% vs 82.9%, P = .04) and devoted more time performing administrative tasks (20.5% ± 15.3% vs 11.1% ± 8.1%, P = .001) than non-AQCV pharmacists. Conversely, AQCV pharmacists spent less time providing clinical care (52.4% ± 14.5% vs 66.2% ± 19.8%, P = .007), were less involved with drug protocol management (71.4% vs 91.4%, P = .05), and performed less order verification than non-AQCV pharmacists. Conclusions Practice patterns differ between inpatient pharmacists with and without AQCV. Further research is needed to determine whether AQCV credentialing improves patient outcomes and to delineate what specific tasks performed by inpatient cardiology pharmacists may improve patient outcomes.
Exciting Advances in the Pathogenesis of Neoplastic and Nonneoplastic Lung Diseases, Their Diagnosis, Prognosis, and Treatment
Roden, Anja C.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 24, 2018 | Volume: 142 | Issue: 8 | Pages: 891-892

10.5858/arpa.2018-0222-ed | PMID 30040454 Get It